Opioid Shareholders 

MANHATTAN — A hyper-aggressive campaign by Insys Therapeutics directors to get doctors to push Subsys, a fentanyl sublingual spray, for off-label uses, caused the share price to plummet by 75 percent, shareholders say in a federal class action.

%d bloggers like this: